Human papillomaviruses (HPVs) are linked to approximately 5% of all cancers, with a notable rise in HPV-positive oropharyngeal cancers. Despite the potential of vaccines to reduce HPV-related diseases, challenges such as vaccine hesitancy, limited global access, and the inability to cover all cancer-causing HPV types emphasize the need for targeted therapeutics. Current treatments, though often effective, cause significant side effects. Our research aims to identify novel therapeutic targets by studying HPV-host interactions. We specifically investigate the E2-TOPBP1 centered complex (ETCC), critical for the HPV16 lifecycle. Collaborating with experts, we have demonstrated that ETCC is essential for HPV16's plasmid segregation and activating the DNA damage response. By understanding the ETCC's role in HPV-associated infections and cancers, we hope to develop targeted therapies that minimize overtreatment and improve patient outcomes.
